A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular Lymphoma
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Duvelisib (Primary) ; Nivolumab
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Richter's syndrome
- Focus Adverse reactions
Most Recent Events
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 21 Jun 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 21 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.